Forte Biosciences Inc expected to post a loss of 43 cents a share - Earnings Preview

Forte Biosciences

11/08/2021 03:38

* Forte Biosciences Inc  FBRX.OQ   FBRX.O  is expected to show a
no change in quarterly revenue when it reports results on August
10 (estimated). 
​* Refinitiv's mean analyst estimate for Forte Biosciences Inc
is for a loss of 43 cents per share. For the same quarter last
year, the company reported a loss of $9.52 per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Forte
Biosciences Inc is $90​, about 69% above​ its last closing price
of $27.91. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.45       -0.52      -0.36     Beat    31.4
 Dec. 31 2020              -0.57      -0.37     Beat    35.5
 Sep. 30 2020  -0.54       -0.54      -0.45     Beat    16.7​
 Jun. 30 2020  -0.19       -0.19      -9.52     Missed  -4,910
                                                        .5
 Mar.          ​           -6.60      -6.45     Beat    2.3​
 31​ 2020​                                              
 Dec. 31 2019  -8.58       -8.55      -7.50     Beat    12.3​
 Sep. 30 2019  -10.33      -10.49     -11.70    Missed  -11.5
 Jun. 30 2019  -11.26      -11.34     -10.80    Beat    4.8
 This summary was machine generated August 11 at 02:38 GMT.  All
figures in US dollars unless otherwise stated